Weifa ASA operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Weifa ASA with three other
miscellaneous service companies in Europe:
of the United Kingdom
sales of £30.18 million [US$36.94 million]
(36.94 million Euro [US$40.19 million]
of which 100%
was Regenerative Medicine), and
GW Pharmaceuticals PLC
based in the United Kingdom
(£28.54 million [US$34.93 million]
of which 78%
was Sativex R&D).
Weifa ASA reported sales of NOK 332.04 million (US$40.22 million)
December of 2015.
increase of 52.4%
versus 2014, when the company's sales were NOK 217.86 million.